EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intrahepatic cholestasis of pregnancy associated with azathioprine: first quantitative disproportionality analysis using the FDA adverse event reporting system

Yonghoon Kwon, Nai Lee, Yun Kim

Journal of Pharmacy & Pharmaceutical Sciences · 2025

DOI: 10.3389/jpps.2025.15527 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy & Pharmaceutical Sciences, 2025. Verfasst von Yonghoon Kwon und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Daegu Catholic University, Gyeongsan, Republic of Korea. Hauptthemen laut MEDLINE: Azathioprine, Cholestasis, Intrahepatic, Pregnancy Complications, Immunosuppressive Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Azathioprine (AZA) is an immunosuppressant approved for renal transplant rejection and rheumatoid arthritis. Recent FDA alerts have raised concerns about its link to intrahepatic cholestasis of pregnancy (ICP), a condition with serious maternal and fetal risks. This study used disproportionality analysis as a hypothesis-generating approach to evaluate the reporting association between AZA and ICP during pregnancy and to compare AZA with other drugs previously implicated in ICP.

Methods

A retrospective pharmacovigilance study was conducted using the FDA Adverse Event Reporting System (FAERS) reports from 1968 to Q2 2024. Disproportionality analysis was performed using reporting odds ratios (RORs), with statistical significance defined as a lower limit of the 95% confidence interval (CI) >1 and at least three unique cases. Subgroup analyses were conducted by pregnancy status and underlying autoimmune indications, and comparative analyses were performed against drugs previously reported to induce ICP.

Results

Among 35,576 AZA-related reports, 67 specifically documented ICP. A strong signal was detected for ICP ROR025 = 153.0; IC025 = 5.8; EBGM05 = 144.37), ranking among the highest AZA-associated adverse events. In pregnant women, ICP also showed a significant signal (ROR025 = 5.46; IC025 = 1.93; EBGM05 = 5.31). Subgroup analyses by indication revealed elevated risks in Crohn’s disease (ROR025 = 66.99; IC025 = 4.8; EBGM05 = 64.73), and Colitis ulcerative (ROR025 = 9.01; IC025 = 1.95; EBGM05 = 9.95). Comparative analyses demonstrated that AZA had a higher proportion of ICP cases than other drugs reported to induce ICP.

Conclusion

This pharmacovigilance analysis identifies a disproportionality signal suggesting a possible association between AZA and intrahepatic cholestasis of pregnancy. These hypothesis-generating findings underscore the importance of cautious use and clinical vigilance when prescribing AZA to women of reproductive age.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzathioprineCholestasis, IntrahepaticPregnancy ComplicationsImmunosuppressive AgentsHumansFemalePregnancyUnited StatesAdverse Drug Reaction Reporting SystemsUnited States Food and Drug AdministrationRetrospective StudiesPharmacovigilanceAdult

Stichwörter der Autor:innen

azathioprineintrahepatic cholestasis of pregnancypharmacovigilancepregnancy safetysignals of disproportionate reporting

Substanzen

AzathioprineImmunosuppressive Agents

Autor:innen und Institutionen

  • College of Pharmacy, Daegu Catholic University, Gyeongsan, Republic of Korea.

Zitieren

APA

Kwon, Y., Lee, N., & Kim, Y. (2025). Intrahepatic cholestasis of pregnancy associated with azathioprine: first quantitative disproportionality analysis using the FDA adverse event reporting system. Journal of Pharmacy & Pharmaceutical Sciences. https://doi.org/10.3389/jpps.2025.15527

Vancouver

Kwon Y, Lee N, Kim Y. Intrahepatic cholestasis of pregnancy associated with azathioprine: first quantitative disproportionality analysis using the FDA adverse event reporting system. Journal of Pharmacy & Pharmaceutical Sciences. 2025. doi:10.3389/jpps.2025.15527

BibTeX
@article{Kwon2025,
  author = {Kwon, Yonghoon and Lee, Nai and Kim, Yun},
  title = {Intrahepatic cholestasis of pregnancy associated with azathioprine: first quantitative disproportionality analysis using the FDA adverse event reporting system},
  journal = {Journal of Pharmacy & Pharmaceutical Sciences},
  year = {2025},
  doi = {10.3389/jpps.2025.15527}
}
Kostenlos starten →